Aveo: FDA OKs FOTIVDA® (tivozanib) for Relapsed or Refractory Advanced Renal Cell Carcinoma

 AVEO Oncology (Nasdaq: AVEO) today announced that the U.S. Food and Drug Administration (FDA) has approved FOTIVDA® (tivozanib) for the treatment of adults with relapsed or refractory advanced renal cell carcinoma (RCC) who have received two or more prior systemic therapies. FOTIVDA is an oral, next-generation vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI).

https://investor.aveooncology.com/news-releases/news-release-details/aveo-oncology-announces-us-fda-approval-fotivdar-tivozanib